Ebronucimab in Chinese patients with hypercholesterolemia---A randomized double-blind placebo-controlled phase 3 trial to evaluate the efficacy and safety of ebronucimab

• Main Authors: Yanyan Zhang (Author), Zhaohui Pei (Author), Beijian Chen (Author), Yanling Qu (Author), Xiaolin Dong (Author), Binge Yu (Author), Guoqin Wang (Author), Fang Xu (Author), Dongmei Lu (Author), Zhimei He (Author), Benchao Chen (Author), Lei Ma (Author), Max Wang (Author), Baiyong Li (Author), Michelle Xia (Author), Bo Zheng (Author), Yong Huo (Author)
• Format: Book
• Published: Elsevier, 2024-09-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Randomized clinical trials (RCTs) of PCSK9 monoclonal antibody(mAb) specifically for Chinese patients have been limited. This multi-center RCT is to clarify the efficacy and safety of a novel mAb, Ebronucimab, in Chinese patients. Patients diagnosed with primary hypercholesterolemia, including Heter...